Bank of America
COCP icon

Bank of America’s Cocrystal Pharma COCP Stock Holding History

Bank of America’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,083
Closed -$8.89K – 5956
2025
Q4 		$8.89K Sell
9,083
-9
-0.1% -$10 ﹤0.01% 6181
2025
Q3 		$11.4K Sell
9,092
-9
-0.1% -$14 ﹤0.01% 7179
2025
Q2 		$13.6K Buy
9,101
+79
+0.9% +$118 ﹤0.01% 7133
2025
Q1 		$12.8K Buy
9,022
+1
+0% +$2 ﹤0.01% 7073
2024
Q4 		$18.2K Sell
9,021
-29
-0.3% -$58 ﹤0.01% 6866
2024
Q3 		$15.9K Buy
9,050
+17
+0.2% +$33 ﹤0.01% 6792
2024
Q2 		$21K Buy
9,033
+58
+0.6% +$113 ﹤0.01% 6731
2024
Q1 		$12.6K Sell
8,975
-4
-0% -$6 ﹤0.01% 6840
2023
Q4 		$15.5K Sell
8,979
-49
-0.5% -$87 ﹤0.01% 6842
2023
Q3 		$16.9K Buy
9,028
+53
+0.6% +$133 ﹤0.01% 6738
2023
Q2 		$21.4K Hold
8,975
– – ﹤0.01% 6692
2023
Q1 		$17.9K Sell
8,975
-16
-0.2% -$36 ﹤0.01% 6784
2022
Q4 		$17.5K Buy
8,991
+16
+0.2% +$41 ﹤0.01% 6773
2022
Q3 		$31K Hold
8,975
– – ﹤0.01% 6860
2022
Q2 		$44K Hold
8,975
– – ﹤0.01% 6893
2022
Q1 		$59K Sell
8,975
-18
-0.2% -$120 ﹤0.01% 7103
2021
Q4 		$70K Buy
8,993
+13
+0.1% +$133 ﹤0.01% 7057
2021
Q3 		$113K Sell
8,980
-3
-0% -$40 ﹤0.01% 6653
2021
Q2 		$134K Buy
8,983
+3
+0% +$46 ﹤0.01% 6338
2021
Q1 		$149K Hold
8,980
– – ﹤0.01% 6221
2020
Q4 		$146K Hold
8,980
– – ﹤0.01% 5788
2020
Q3 		$100K Buy
8,980
+5
+0.1% +$91 ﹤0.01% 5704
2020
Q2 		$163K Hold
8,975
– – ﹤0.01% 5381
2020
Q1 		$76K Hold
8,975
– – ﹤0.01% 5669
2019
Q4 		$53K Sell
8,975
-168
-2% -$1.68K ﹤0.01% 6239
2019
Q3 		$225K Sell
9,143
-77
-0.8% -$2K ﹤0.01% 5598
2019
Q2 		$259K Buy
9,220
+79
+0.9% +$2.35K ﹤0.01% 5483
2019
Q1 		$299K Buy
9,141
+166
+2% +$6.07K ﹤0.01% 5317
2018
Q4 		$388K Hold
8,975
– – ﹤0.01% 5100
2018
Q3 		$269K Buy
8,975
+8,961
+64,007% +$401K ﹤0.01% 5317
2018
Q2 		$1K Sell
14
-42
-75% -$1.56K ﹤0.01% 6961
2018
Q1 		$4K Buy
+56
New +$3.5K ﹤0.01% 6801

Other funds holding COCP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bank of America's COCP Position: Q1 2026 in Review

Bank of America sold out of Cocrystal Pharma (COCP) in Q1 2026, closing a stake of 9,083 shares — an estimated $8.89K sold.

Bank of America first reported a position in COCP in Q1 2018 and held it in 32 quarters. The position peaked at $388K in Q4 2018. 26 funds tracked by Wall St. Rank hold COCP as of Q1 2026.

  • Bank of America reported no remaining Cocrystal Pharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 9,083 Cocrystal Pharma shares in Q1 2026, an estimated $8.89K.
  • Bank of America first reported a position in Cocrystal Pharma in Q1 2018 and held it in 32 quarters.
  • Bank of America's Cocrystal Pharma position peaked at $388K in Q4 2018.
  • 26 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.